Company intelligence / Profile preview

Furixi Pharmaceutical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Furixi Pharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases, particularly type 2 diabetes. The company's lead candidate is a GPR119 agonist designed to improve glycemic control by stimulating insulin secretion and enhancing GLP-1 levels. Furixi aims to address unmet needs in metabolic health through targeted mechanisms that offer improved efficacy and safety profiles compared to existing treatments. Headquartered in China, the company is advancing its pipeline through early to mid-stage clinical trials.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Furixi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Furixi Pharmaceutical.

Explore the full profile